Q: What antithrombotic therapy should I use for my patient with atrial fibrillation who underwent percutaneous coronary intervention or had an acute coronary syndrome?

A: Double therapy (ie, an oral anticoagulant and a P2Y12 inhibitor such as clopidogrel) is reasonable for most patients, ie, those with average risk of ischemia, elevated risk of bleeding, or both. However, in certain patients, particularly those with atrial fibrillation who undergo percutaneous coronary intervention or those at higher risk of ischemia, triple therapy (ie, an oral anticoagulant, a P2Y12 inhibitor, and low-dose aspirin) may be reasonable initially.

The current (2019) guidelines on atrial fibrillation from the American College of Cardiology, American Heart Association, and Heart Rhythm Society (ACC/AHA/HRS) recommend that, if triple therapy is used initially, double therapy (ie, discontinuing the aspirin) can be considered after 4 to 6 weeks.1 The 2017 guidelines from the European Society of Cardiology (ESC)2 are slightly different: triple therapy for at least 1 month after percutaneous coronary intervention and up to 6 months if the patient is at high risk of ischemia. The risk of thrombosis with double therapy must be weighed against the risk of bleeding with triple therapy.

DOUBLE VS TRIPLE THERAPY
The safety and efficacy of double vs triple therapy has been evaluated in several randomized controlled trials.4–8

The WOEST trial4 (What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting?) compared double vs triple therapy, with a vitamin K antagonist (eg, warfarin) and dual antiplatelet therapy. While oral anticoagulation and antiplatelet therapy separately increase the risk of bleeding, the risk is even higher when they are combined, and higher still with triple therapy.3

The risk of thrombosis should be balanced with the risk of bleeding.
outcome of mortality and ischemic events) compared with triple therapy using a vitamin K antagonist as the oral anticoagulant.

Gargiulo et al,9 in a meta-analysis of these trials,5–8 found that double therapy posed a lower risk of bleeding, defined as International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleeding (risk ratio 0.62, 95% confidence interval [CI] 0.47–0.81, number needed to treat 14). However, the trials were not specifically powered to detect a difference in ischemic event rates. While there was no difference in the rates of all-cause mortality, cardiovascular mortality, or trial-defined major adverse cardiac events, there was a small but significant increase in the risk of stent thrombosis with double therapy (risk ratio 1.59, 95% CI 1.01–2.50, number needed to harm 273).9

■ DIRECT ORAL ANTICOAGULANTS VS VITAMIN K ANTAGONISTS

Comparing the type of anticoagulant, direct oral anticoagulant therapy was at least noninferior to vitamin K antagonist therapy in regard to bleeding outcomes, and noninferior in regard to ischemic outcomes.5–8 The numbers needed to treat with a direct oral anticoagulant to prevent 1 bleeding event from a vitamin K antagonist ranged from 10 to 24. There were no significant differences in ischemic outcomes between the 2 types of anticoagulants. However, as we said, these trials were not specifically powered to detect differences in ischemic events; the primary outcome of interest was bleeding.

■ CURRENT GUIDELINES

Current ACC/AHA/HRS guidelines1 recommend anticoagulation in atrial fibrillation if the CHA2DS2-VASc score is 2 or higher in men and 3 or higher in women. (To calculate the CHA2DS2-VASc score, 1 point each is given for congestive heart failure, hypertension, age greater than 65 [or 2 points for age > 75], diabetes, stroke [2 points], vascular disease, and female sex category, for a maximum of 9 points.)

First-line oral anticoagulation therapy has traditionally consisted of a vitamin K antagonist but now includes the direct oral anticoagulants, such as dabigatran, rivaroxaban, apixaban, and edoxaban,9 which have become the preferred agents due to safety data.

For patients with atrial fibrillation requiring combined antithrombotic therapy for acute coronary syndromes or percutaneous coronary intervention, the ACC/AHA/HRS,1 American College of Chest Physicians (ACCP),10 and ESC2 guidelines recommend double or short-term triple therapy with an oral anticoagulant (vitamin K antagonist, rivaroxaban, or dabigatran) and clopidogrel, tailored on the basis of thrombotic risk and bleeding risk (discussed further below).

The ESC guidelines2 specifically recommend against the combination of a direct oral anticoagulant plus prasugrel or ticagrelor, given a lack of evidence and potential for increased bleeding based on registry data. The ACC/AHA/HRS guidelines1 allow ticagrelor as an alternative to clopidogrel in dual therapy with a vitamin K antagonist but not a direct oral anticoagulant.

The ACCP guidelines10 further recommend that direct oral anticoagulants be used at licensed dosing levels, particularly important with rivaroxaban and dabigatran, which were given in lower, nonapproved doses in their respective clinical trials.5,6

The current guidelines regarding direct oral anticoagulants do not include apixaban or edoxaban. However, based on recent trials of these newer agents,7,8 double therapy with apixaban or edoxaban and clopidogrel may soon be formally recommended.

■ PATIENTS AT HIGH THROMBOTIC RISK

In their 2017 guidelines,7 the ESC recommended triple therapy for at least 1 month and up to 6 months in the subset of patients who underwent percutaneous coronary intervention or who had a high thrombotic risk. The ESC2 and ACCP10 guidelines enumerate these risk factors, which include:

• Prior stent thrombosis while receiving antiplatelet therapy
• Stenting of the last remaining patent coronary artery
• Diffuse multivessel disease, especially in patients with diabetes
• Chronic kidney disease
At least 3 stents implanted
At least 3 lesions treated
Bifurcation with 2 stents implanted
Total stent length greater than 60 mm
Treatment of a chronic total occlusion
Left main stenting.

**PATIENTS AT HIGH BLEEDING RISK**

The risk of thrombotic events should be balanced with the risk of bleeding. The most commonly used tool for assessing bleeding risk is the HAS-BLED score, in which points are given for hypertension, abnormal kidney or liver function, stroke, bleeding, labile international normalized ratio, elderly status, and use of drugs that predispose to bleeding or use of alcohol. A HAS-BLED score of 3 or more indicates a higher risk of bleeding.

The 2018 ACCP atrial fibrillation guidelines recommend using the HAS-BLED score, particularly in patients taking vitamin K antagonists, to tailor discussion of risk of bleeding while on anticoagulant therapy. While rarely a reason to avoid anticoagulation, a high HAS-BLED score should prompt clinicians to aggressively treat the modifiable aspects of the score to reduce the risk of bleeding. This is particularly important to consider when additional antiplatelet therapy is required after percutaneous coronary intervention.

**DURATION OF COMBINED ANTITHROMBOTIC THERAPY**

The overall duration of antiplatelet therapy is based on the indication for it (stable ischemic heart disease with percutaneous coronary intervention, acute coronary syndrome, and type of stent used). Patients who have stable ischemic heart disease who undergo percutaneous coronary intervention with bare-metal stents require at least 1 month of antiplatelet therapy. Those who receive drug-eluting stents require at least 3 months of antiplatelet therapy if they have a high risk of bleeding; otherwise, 6 months is preferred. In those with acute coronary syndrome with or without percutaneous intervention, antiplatelet therapy is recommended for at least 6 months if there is a high risk of bleeding; otherwise, 12 months is preferred.

Whether to start patients on triple therapy and its duration is another consideration. The duration of initial triple therapy is tailored on the basis of individual thrombotic and ischemic risk, and the guidelines offer multiple strategies. In summary:

- For patients at low thrombotic risk, double therapy alone (ACC/AHA/HRS) or 1 to 6 months of triple therapy (ACCP and ESC) can be considered, with shorter durations of triple therapy if bleeding risk is high (HAS-BLED score ≥ 3).
- For those at high thrombotic risk, all guidelines recommend triple therapy for 1 to 6 months, again tailored to bleeding risk.

**TAKE-HOME MESSAGES**

Combined antithrombotic therapy in patients with atrial fibrillation with acute coronary syndrome or percutaneous coronary intervention requires a balanced consideration of bleeding risk vs ischemic risk.

For most patients with average ischemic risk, double therapy with a vitamin K antagonist or a direct oral anticoagulant—specifically rivaroxaban, dabigatran, and, probably soon, apixaban and edoxaban—with clopidogrel is reasonable. Direct oral anticoagulants, at licensed dosing, have become the preferred agents for many patients due to the lower risk of bleeding.

For patients at increased ischemic risk and average or lower bleeding risk, triple therapy for 1 to 6 months may be considered. The duration of triple therapy is tailored to the risk of bleeding, with a shorter duration if bleeding risk is high (eg, HAS-BLED score ≥ 3, recent bleeding).

Given the current evidence, clopidogrel should be used in combined antithrombotic therapy. Ticagrelor can be considered for double therapy with a vitamin K antagonist.

This is a complex and evolving field, and as new evidence comes out and technology improves, our practice of using combined antithrombotic therapies in these high-risk patients will undoubtedly continue to change.

**DISCLOSURES**

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.
REFERENCES


Address: Neera Agrwal, MD, PhD, Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, AZ 85054; agrwal.neera@mayo.edu